Nov 062013
J&J and its subsidiaries have agreed to pay 2.2 billion to resolve criminal and civil investigations for misbranding antipsychotic drugs and paying kickbacks to pharmacists, U.S. DOJ said.
J&J and its subsidiaries have agreed to pay 2.2 billion to resolve criminal and civil investigations for misbranding antipsychotic drugs and paying kickbacks to pharmacists, U.S. DOJ said.